Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

pazopanib 2Trastuzumab 2Sorafenib 2Radiotherapy 2Paclitaxel 2Cisplatin 2tipifarnib 1sargramostim 1crolibulin 1aldesleukin 1Taxes 1Tamoxifen 1Radiotherapy, Intensity-Modulated 1Magnetic Resonance Spectroscopy 1Interleukin-12 Subunit p35 1Interleukin-12 1Hydroxyurea 1Gefitinib 1Fluorouracil 1Fluorodeoxyglucose F18 1Filgrastim 1Everolimus 1Doxorubicin 1CUDC-907 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Carcinoma, Anaplastic × crolibulin × Clear all
NCT01240590 2017-04-10

A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 15 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡